Dozi ngapi za COVID-19 zinahitajika?

Ratiba ya chanjo ya COVID-19 ina dozi 6.

Madhara ya COVID-19 ni yapi?

Madhara ya kawaida ni pamoja na: Maumivu ya tumbo, Anaphylaksi, Angiodema, Maumivu ya viungo, Kupooza kwa Bell.

Nani hapaswi kupata COVID-19?

Vikwazo ni pamoja na: Ugonjwa mkali wa papo hapo na homa, Umri chini ya kiwango cha chini kinachopendekezwa, Mshituko mkali baada ya dozi ya awali, Mzio kwa kijenzi cha chanjo, Ugonjwa wa kutokwa na damu.

COVID-19

mRNAWHO: COVID

Muhtasari

Chanjo ya COVID-19 ya mRNA ni teknolojia mpya ya chanjo inayotumia RNA ya mjumbe (messenger RNA) kusababisha seli za mwili kuzalisha protini ya spike ya SARS-CoV-2, na hivyo kuchochea mwitikio wa kinga. Chanjo kuu mbili za mRNA ni Comirnaty (Pfizer-BioNTech) na Spikevax (Moderna). Teknolojia ya mRNA iliendelezwa kwa haraka wakati wa janga la COVID-19 (2020-2023) na imekuwa mojawapo ya maendeleo muhimu zaidi ya dawa katika karne ya 21. Chanjo hizi ziliidhinishwa kwa matumizi ya dharura mwishoni

Maudhui haya bado hayapatikani kwa lugha yako. Toleo la Kiingereza linaonyeshwa.

Pregnancy: Recommended (WHO, ACIP).

COVID-19 mRNA vaccines (Comirnaty, Spikevax) are safe and recommended during pregnancy.

Pregnant women are at increased risk of severe COVID-19, ICU admission, preterm delivery, and maternal death.
Vaccination during pregnancy provides passive antibody transfer to the neonate.
Can be administered at any gestational age. No evidence of teratogenicity or adverse pregnancy outcomes in large observational studies (V-safe, VAERS, global registries).
WHO SAGE and CDC/ACIP both recommend COVID-19 vaccination for pregnant individuals.

Maudhui haya bado hayapatikani kwa lugha yako. Toleo la Kiingereza linaonyeshwa.

Breastfeeding: Safe and recommended.

COVID-19 mRNA vaccines are safe during breastfeeding. mRNA does not enter breast milk in functional form. Antibodies generated by maternal vaccination are detected in breast milk and may provide passive protection to the breastfed infant.

Maudhui haya bado hayapatikani kwa lugha yako. Toleo la Kiingereza linaonyeshwa.

Pediatric use:

Comirnaty (Pfizer-BioNTech): approved from 6 months of age. Age-adjusted doses:
- 6 months–4 years: 3 µg (0.2 mL), 3-dose primary series.
- 5–11 years: 10 µg (0.2 mL).
- ≥12 years: 30 µg (0.3 mL) — adult dose.
Spikevax (Moderna): approved from 6 months of age. Age-adjusted doses:
- 6 months–5 years: 25 µg (0.25 mL), 2-dose series.
- 6–11 years: 50 µg (0.5 mL).
- ≥12 years: 50–100 µg — adult dose.
Annual updated booster formulations target circulating variants.
Myocarditis risk is lower in children <12 years than in adolescent/young adult males.

Maudhui haya bado hayapatikani kwa lugha yako. Toleo la Kiingereza linaonyeshwa.

Geriatric use: Priority group for vaccination.

Adults ≥65 years are at highest risk of severe COVID-19 outcomes and are a priority group for vaccination and boosters.
Immune response may be lower (immunosenescence), hence the recommendation for regular booster doses.
High-dose and adjuvanted formulations are not available for mRNA vaccines, but additional booster doses compensate.
Adverse event profile is generally milder in older adults compared to younger recipients (less reactogenicity).
Annual updated boosters strongly recommended for all adults ≥65 years.

Madhara

Ya kawaida sana

Maumivu ya viungo
Baridi mwilini
Uchovu
Homa
Maumivu ya kichwa
Maumivu kwenye eneo la sindano
Uwekundu kwenye eneo la sindano
Uvimbe kwenye eneo la sindano
Kujisikia vibaya
Maumivu ya misuli

Ya kawaida

Maumivu ya tumbo
Kuharisha
Kizunguzungu
Kusinzia
Kulia kupita kiasi
Ugumu kwenye eneo la sindano
Kuwashwa kwenye eneo la sindano
Joto kwenye eneo la sindano
Kukosa usingizi
Kutokuwa na utulivu
Kupoteza hamu ya kula
Kuvimba kwa tezi za limfu
Kichefuchefu
Jasho la usiku
Kupungua kwa uwezo wa kusogeza mkono
Kutapika

Vizuizi

KamiliUmri chini ya kiwango cha chini kinachopendekezwa
KamiliMshituko mkali baada ya dozi ya awali
KamiliMzio kwa kijenzi cha chanjo
TahadhariUgonjwa mkali wa papo hapo na homa
TahadhariUgonjwa wa kutokwa na damu
TahadhariHistoria ya ugonjwa wa Guillain-Barré
TahadhariKukandamizwa kwa kinga kwa kiasi
TahadhariUtoaji wa hivi karibuni wa immunoglobulini
TahadhariThrombocytopenia

Ratiba ya chanjo

Kipimo	Siku tangu iliyotangulia	Kipindi cha umri
Kipimo 1	—	12 miaka+
Kipimo 1	365d	12 miaka+
Kipimo 2	21d	—

Inalinda dhidi ya

COVID-19

Dalili

UfiniInapendekezwa
MyamaInapendekezwa
Saudi ArabiaInapendekezwa
Sudan KusiniInapendekezwa
MalesiaInapendekezwa
KatariInapendekezwa
NikaraguaInapendekezwa
Saint Vincent na GrenadinesInapendekezwa
KolombiaInapendekezwa
UswidiInapendekezwa

Pata chanjo kabla ya safari yako

Unajua chanjo unayohitaji? Vizuri. Hujui? Tuambie tu unaenda wapi — tutapata chanjo zinazofaa na kliniki. Bure, bila masharti.

Maudhui katika ukurasa huu ni kwa madhumuni ya habari na elimu pekee. Hayaundi ushauri wa kitabibu, utambuzi, au mapendekezo ya matibabu. Ikiwa una wasiwasi wa kiafya, wasiliana na mtaalamu wa afya aliyeidhinishwa. Medova si mtoa huduma za matibabu.

Masharti kamili ya matumizi

Muhtasari

Kipimo

Siku tangu iliyotangulia

Kipindi cha umri

Kipimo 1

—

12 miaka+

Kipimo 1

365d

12 miaka+

Kipimo 2

21d

—

Maeneo

Afya na usalama

Zana na rasilimali

COVID-19